Arix Bioscience Plc Reports Positive Preliminary Data From Fosmanogepix Phase 2 Study

  • Sep 17, 2019 BST
  • Team Kalkine

Arix Bioscience Plc (LSE: ARIX), has reported about positive preliminary data from ongoing APX001 (fosmanogepix) Phase 2 study in candidemia by its portfolio company Amplyx Pharmaceuticals. A high level of treatment accomplishment at the end of study drug treatment was confirmed by fosmanogepix in the Data Review Committee report.

On 17th September 2019, at the time of writing, GMT 12.36 PM, ARIX shares were trading at GBX 119.00, down by 1.00 points or 0.83% against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK